A small upfront payment, a large horizon
The financial structure tells the story of an early bet. Disco receives $40 million upfront, a modest sum by big pharma standards, while the bulk of the deal's value, up to $2.5 billion, depends on milestones that will be reached only if the science succeeds. Disco will also be eligible for tiered royalties on worldwide net sales of any resulting medicines.
Under the agreement, Disco is responsible for research and discovery, and AbbVie gains the right to exclusively license selected programs for further development. That option applies only after Disco completes specified research, and neither company disclosed how many programs could be covered or when any might enter clinical trials.
Two keys for one lock
The concept behind the partnership is elegant. Many cancer drugs fail because the protein they target also appears on healthy cells, causing damaging side effects.















